Dr. Reddy's Laboratories
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 weeks.
- Recent price momentum is +15.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 3.0% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 41.4x | Better than 13% |
| Forward P/E | 27.0x | Better than 22% |
| Price / Sales | 3.5x | Better than 35% |
| P/E vs own 5-yr range | 99th pctl | Better than 4% |
Growth C+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 11.0% | Better than 67% |
| Net income CAGR (3Y) | -1.7% | Better than 38% |
| Free cash flow CAGR (3Y) | -22.9% | Better than 16% |
Profitability B+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 52.8% | Better than 66% |
| Operating margin | 14.9% | Better than 64% |
| Net margin | 12.8% | Better than 66% |
| Return on equity | 12.1% | Better than 59% |
| Return on invested capital | 10.3% | Better than 69% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 22.2% | Better than 97% |
| 6-month return | 10.3% | Better than 73% |
| 12-month return (ex latest month) | -4.4% | Better than 29% |
| Distance below 52-week high | 4.3% | Better than 96% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.8x | Better than 51% |
| Debt to assets | 13.3% | Better than 64% |
| Interest coverage | 15.7x | Better than 79% |
| Free cash flow / net income | 42.8% | Better than 11% |
Analyst View D+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 66.7% | Better than 41% |
| Upside to average target | -3.3% | Better than 2% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 14.83
- Open
- 14.88
- Day range
- 14.86 - 15.10
- Avg price
- 14.91
- Volume
- 1.75M
- Turnover
- 26.06M
- Turnover ratei
- 0.29%
- Volume ratioi
- 0.84
- Amplitudei
- 1.65%
- 52-week rangei
- 11.28 - 15.56
Valuation
- P/Ei
- 27.02
- P/E (TTM)i
- 41.36
- P/Bi
- 3.00
- EPSi
- 0.55
- Book value / shi
- 4.96
- Net profit
- 459.35M
- Net assets
- 4.14B
Share structure
- Market cap
- 12.41B
- Float capi
- 8.94B
- Shares out
- 833.66M
- Float sharesi
- 600.65M
Dividend & listing
- Div yield (TTM)i
- 0.56%
- Dividend (TTM)
- 0.08
- Listing date
- 1970-01-01
4.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-16.48M net over the window
Short interest
- Shares short
- 25.30M
- % of floati
- 3.04%
- Days to coveri
- 7.81
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Dr. Reddy's Laboratories (RDY)?
Dr. Reddy's Laboratories last traded at 14.89. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Dr. Reddy's Laboratories's market cap?
About 12.41B.
What is the P/E ratio of Dr. Reddy's Laboratories?
The trailing twelve-month P/E is 41.36, above its own 5-year average of 22.59 — toward the top of its historical range (98.88% percentile). See the Valuation tab for the full history.
Does Dr. Reddy's Laboratories pay a dividend?
Yes. The trailing dividend yield is 0.56%. The 2025 payout fell 81% from 2024 - a real reduction, not rounding noise. See the Dividends tab for the full payment history.
Is Dr. Reddy's Laboratories a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 14.40, which implies 3.3% downside from the current price. This is not investment advice.
What is Dr. Reddy's Laboratories's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Dr. Reddy's Laboratories a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:31 · For reference only, not investment advice and not tailored to your situation.
Dr. Reddy's Laboratories discussion 0 comments